Japanese government panel OKs expensive gene therapy for rare disease
A health ministry panel approved Wednesday the production and sales of a gene therapy for treating spinal muscular atrophy, a rare incurable disease that destroys muscle function through a decrease in motor neuron cells.
At this time, the one-time-only gene therapy, developed by Swiss drug giant Novartis AG, will cover patients below two years old with abnormalities in their genes to make proteins necessary for maintaining motor nerves. Novartis estimates 15 to 20 children a year are likely to receive treatment using the drug in Japan.
In the therapy, the proteins will be created after the genes carried by adeno-associated viruses are delivered to motor nerves through intravenous drips.
In an overseas clinical trial, all of 15 severe SMA patients who used the therapy were able to live without an artificial ventilator. About 75 percent of such patients would be expected to die or need an artificial ventilator when they reached the age of 13.6 months if no treatment was offered.
The therapy, which has already been approved in the United States, is expensive, costing the dollar equivalent of ¥230 million for a one-time infusion.